Top Back to top

Evaluating the Impact of ABO Compatibility on Allogeneic Stem Cell Transplantation Outcomes

Transplant Complications Working Party (TCWP)
Study type:
Study number:
84110143
Type of Stem Cell Treatment:
Allogeneic
Diseases:
All diseases
Short title:
ABO Compatibility
Primary objective:
 
Key inclusion criteria:
 
Country:
All EBMT member countries
Principal investigator:
Mustafa G├╝ven
EBMT Study coordinator:
William Boreland
Study coordinator email:
william.boreland@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Recipients who may access the data:
Paris Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results